Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance

The Journal of Infectious Diseases
Damon FrancisGrant Dorsey

Abstract

Recent clinical trials from Uganda have shown that the risk of failure following antimalarial therapy varies geographically. We tested the hypothesis that geographic differences in the response to therapy could be explained by differences in the prevalence of known molecular markers of drug resistance. Samples from 2084 patients treated with chloroquine (CQ) plus sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) plus SP were tested for the presence of known molecular markers of resistance. Differences in the risk of treatment failure across 6 sites were compared, and age and complexity of infection were controlled for. The prevalence of molecular markers of drug resistance was high at all of the sites: 61%-91% of patients were infected with parasites containing the pfcrt Thr-76 mutation and dhfr/dhps quintuple mutation. The risk of treatment failure decreased with increasing transmission intensity for both CQ plus SP (73% to 19%) and AQ plus SP (38% to 2%). Restricting the analyses to patients infected with parasites containing all 6 mutations of interest did not affect these trends. The risk of treatment failure was inversely proportional to transmission intensity and was not explained by differences in molecular markers of ...Continue Reading

Citations

Jun 12, 2013·Trends in Parasitology·Nicole MideoAndrew F Read
Oct 20, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Harald NoedlCharles Knirsch
Jan 13, 2010·Antimicrobial Agents and Chemotherapy·Samuel L NsobyaPhilip J Rosenthal
Mar 21, 2009·Antimicrobial Agents and Chemotherapy·Alisa P AlkerStephen A Ward
Feb 19, 2009·Antimicrobial Agents and Chemotherapy·Ina DanquahFrank P Mockenhaupt
Jan 16, 2007·Clinical Microbiology Reviews·David J Conway
Mar 18, 2011·BMC International Health and Human Rights·Freddie SsengoobaAdnan A Hyder
Jun 8, 2011·Malaria Journal·Laura R SangaréAndy Stergachis
Sep 8, 2007·Malaria Journal·Christopher V PlowePhilip J Rosenthal
Jan 5, 2010·Malaria Journal·Rachel L PullanSimon Brooker
Sep 8, 2010·Annals of Tropical Medicine and Parasitology·G Akello-AyebareL G Visser
Mar 6, 2013·The American Journal of Tropical Medicine and Hygiene·Rosa Elena Mejia TorresJose Orlinder Nicolas Zambrano
Feb 5, 2010·The Lancet Infectious Diseases·Stephen J RogersonSteven R Meshnick
Jul 4, 2006·Lancet·S Patrick Kachur, Laurence Slutsker
Nov 18, 2015·Malaria Journal·Junior R MatangilaJean-Pierre Van Geertruyden
May 7, 2014·The American Journal of Tropical Medicine and Hygiene·George W MbogoPhilip J Rosenthal
Mar 11, 2015·Antimicrobial Agents and Chemotherapy·Patrick TumwebazePhilip J Rosenthal
Sep 20, 2017·Antimicrobial Agents and Chemotherapy·Stephanie A RasmussenRoland A Cooper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.